-
Target
£800,000
-
Type
Equity
-
Close Date
Nov 30 2018
-
Status
Live
RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.
Tharos
NATURE POWERED BY SCIENCE Advancing Horse Health and Performance through Science-driven Innovation

A pledge is not a commitment. You will be asked to confirm in the next section.
Locked
House
Locked
Overview
- The state of the gut is of critical importance to humans and animals alike. It has a direct effect on health and performance. The impact of the microbiome – including bacteria, fungi and viruses – in the gut is now coming under scrutiny. It is these microbiomes in animals that form the scientific focus of THAROS™.
- 2018 will see the market launch of the first THAROS™. product, EquiNectar® horse feed – the culmination of years of research and development. EquiNectar® is the commercialised form of enzyme rich malt extract (ERME), which has been shown to improve the health and performance of racehorses suffering from common digestive problems.
- Contributing to a four-fold increase in prize money during in-feed trials at one leading race yard, EquiNectar® has been described as “a game-changer” by a leading figure in the sector. The original product is being followed up with the development of alternative formats, and with further potential applications in the equine sector and other animals.

Deal Manager
Agne Pakalniskyte
Lead Investor

Anglo Scientific
The investors and entrepreneurs of Anglo Scientific, strive to build technology led companies underpinned by groundbreaking science that we have either invented ourselves or sourced from gifted third parties. These technologies have the potential to deliver disruptive products to address identified large market opportunities in their areas of expertise: healthcare, security & communications.